Success Metrics

Clinical Success Rate

69.4%

Based on 43 completed trials

Completion Rate

69%(43/62)

Active Trials

17(19%)

Results Posted

114%(49 trials)

Terminated

19(21%)

Phase Distribution

Ph phase_4

Ph phase_1

42%

Ph phase_2

41%

Ph phase_3

Ph early_phase_1

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution88 total trials

Early Phase 1First-in-human

1(1.1%)

Phase 1Safety & dosage

38(43.2%)

Phase 2Efficacy & side effects

37(42.0%)

Phase 3Large-scale testing

7(8.0%)

Phase 4Post-market surveillance

5(5.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

61.4%

43 of 70 finished

Non-Completion Rate

38.6%

27 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(17)

Completed(43)

Terminated(27)

Other(3)

Detailed Status

Completed43

Terminated19

Active, not recruiting13

Withdrawn8

Recruiting4

unknown3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

69.4%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (1.1%)

Phase 138 (43.2%)

Phase 237 (42.0%)

Phase 37 (8.0%)

Phase 45 (5.7%)

Trials by Status

unknown33%

withdrawn89%

completed4348%

recruiting44%

terminated1921%

active_not_recruiting1314%

Recent Activity

17 active trials

Showing 5 of 90

active_not_recruitingphase_2

Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

NCT03587662

recruitingphase_1

Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone

NCT02516423

View all 90 trials

Clinical Trials (90)

Showing 20 of 90 trialsScroll for more

NCT03587662Phase 2

Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Active Not Recruiting

NCT02343042Phase 1

Selinexor and Backbone Treatments of Multiple Myeloma Patients

Recruiting

NCT05451771Phase 1

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Active Not Recruiting

NCT03283917Phase 1

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

Completed

NCT02516423Phase 3

Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone

Terminated

NCT03323151Phase 1

A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

Completed

NCT04068597Phase 1

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Recruiting

NCT03651128Phase 3

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Completed

NCT04998786Phase 2

A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."

Active Not Recruiting

NCT03547700Phase 1

Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

Terminated

NCT03173092Phase 4

A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

Terminated

NCT03763162Phase 2

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Active Not Recruiting

NCT04094961Phase 1

Ixazomib + Pomalidomide + Dexamethasone In MM

Active Not Recruiting

NCT05722405Phase 4

Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma

Recruiting

NCT04009109Phase 2

Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

Active Not Recruiting

NCT02461888Phase 2

Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.

Completed

NCT03618537Phase 2

Ixazomib Maintenance Study in Patients With AL Amyloidosis

Active Not Recruiting

NCT02253316Phase 2

Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

Active Not Recruiting

NCT03590652Phase 2

Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma

Terminated

NCT02412228Phase 2

Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma

Completed

Drug Details

Intervention Type: DRUG
Total Trials: 90